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Inthediscussionsanddebatesaboutghostwritingandphar-
maceutical-industry-sponsored manuscripts, at times the
public, Congress, and the academic community lose sight
of the tangible contribution of the pharmaceutical industry
to the development of valuable new treatments, and the ex-
pansion of knowledge about why drugs work and why they
fail. This valuable work is often done in collaboration with
academicinvestigators,supportedbyindustry.Muchofthis
work is reported as original research in major journals.
However, the broader perspective, as presented in well-
written papers that review a drug or drug class, also de-
serves to be heard. By closing the door to manuscripts
written and supported by industry, we stand the chance of
losing valuable insights and useful experience. The Editors
of this journal have personally reviewed and have seen the
value of some of these papers, which we have heretofore
rejected, and we have pondered how to create an opportu-
nity for their publication.
We have come to the conclusion that we should offer an
alternative for industry-sponsored or supported reviews.
We will, therefore, introduce a new section of the journal,
Academia–Pharma Intersect, with Professor H. M. Pinedo,
M.D., Ph.D., and Howard A. Burris III, M.D., as Section
Editors. The new section will publish papers sponsored and
supportedbyindustry,butincludingacademiccontributors.
All authors must affirm responsibility for the content of
their paper, and all authors, including professional medical
writers hired by the company, will be identified in the by-
line. These industry-sponsored papers, which are expected
to include information about the broader range of therapeu-
tic options relevant to the discussion, will be peer reviewed
and must meet standards of objectivity and fairness.
Our intent is to provide the same high quality of content
found in the rest of the Journal, but from the broader per-
spective found at that intersection where academia and in-
dustry meet.
Bruce A. Chabner, M.D.
Editor-in-Chief, The Oncologist
Clinical Director
Massachusetts General Hospital Cancer Center
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A new section of The Oncologist
Mission: The Academia–Pharma Intersect section of
The Oncologist features manuscripts supported directly or
indirectly by the research-intensive pharmaceutical indus-
try. These papers are subjected to the same stringent peer
review as are all original and review articles. Professional
medical writers will be named as authors, thus ensuring
transparencyandfulldisclosure.Whenpublished,theywill
be endowed with the same PubMed citation as are all peer-
accepted papers in The Oncologist.
Dr. Bruce A. Chabner, Editor-in-Chief:
For the regular monthly issues of The Oncologist, we
will accept papers for peer review only if the article is
written,endorsed,andofferedforpublicationbyallthe
authors identified in the byline. In consideration of the
role of a commercial entity and its employees in offer-
ing papers describing original, previously unpublished
research, we accept that a company has a necessary
role in reporting the work. If a company employee par-
ticipates in the design and execution of a clinical trial
and/ortakespartinthewritingandeditingofthemanu-
scriptdescribingthattrial,itisnotonlyappropriatebut
it is necessary that the employee be recognized as an
author. The reporting of original research involving a
company product may be assisted by a professional
writer hired by the company to organize and/or expe-
dite the manuscript’s submission. This assistance must
be acknowledged by the authors. However, if the ac-
tual writing of the article is done by a professional
medical writer, the article will be considered for pub-
lication only when the professional writer is included
as an author and the role explicitly acknowledged.
With regard to scholarly reviews, we will accept for
peer review manuscripts that are written by academic
researchers and professional writers who are identified
in the byline. The authors must attest that the paper
represents their own work, for which they take full re-
sponsibility,andnottheworkorsoleopinionofacom-
mercial entity. Professional writers should be included
as authors when they draft or otherwise substantially
contribute to the manuscript. If a professional writer
editsthemanuscript,thenatureandsourceofthefinan-
cial support for that role must be clearly described in
the manuscript.
Manuscripts written by a professional medical
writer,supporteddirectlyorindirectlybyapartywitha
commercialinterestinthecontentofthearticle,willbe
considered for peer-accepted publication in the new
section of the Journal called The Academia–Pharma
Intersect, as described in the accompanying editorial
statement.
The Oncologist’s editors and editorial board are responsi-
ble for the strict peer-review, acceptance or rejection of all
submissions.
Section Editors: H. M. Pinedo, M.D., Ph.D.; Howard A.
Burris III, M.D.
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